Rankings / Muscle & Strength

Testosterone (TRT / supraphysiological)

Muscle & Strength · Endogenous androgen (AR agonist)

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

anabolicandrogen-therapycontrolled-substanceprescription
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Testosterone (TRT / supraphysiological) as B (6.8/10) based on strong evidence, strong benefit magnitude, and a med-risk safety profile.

TRAVERSE 2023 (n=5246, high CV risk hypogonadal men) — TRT non-inferior to placebo for MACE; no prostate cancer increase; small increases in atrial fibrillation, VTE, fractures, acute kidney injury.

Studied, labeled, or reported-use context: TRT: testosterone cypionate/enanthate 100-200 mg/week IM/subQ, or daily gel; supraphysiological cycles… — Rx for hypogonadism (Schedule III US as anabolic steroid); illicit supraphysiological use illegal; not individualized guidance.

If you were testing this on yourself

Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.

Can you undo it?

Potentially permanent

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis. Recovery after stopping is usual but not guaranteed, can take many months to years, and a proportion of users do not fully recover endogenous production. Fertility may be affected for the duration and beyond. This is not an experiment you can simply end.

Can you tell if it worked?

Readable — Weeks for levels; months for body composition

Total and free testosterone, haematocrit, oestradiol, PSA — all standard panel items.

What would fool you Measurability is not the constraint here — reversibility is. The relevant question before starting is not whether you will see a change but whether you accept a change you may not be able to undo. Haematocrit rising is the routine monitoring issue and needs a clinician, not a self-adjustment.

What the evidence says

TRAVERSE 2023 (n=5246, high CV risk hypogonadal men) — TRT non-inferior to placebo for MACE; no prostate cancer increase; small increases in atrial fibrillation, VTE, fractures, acute kidney injury. Reduced progression to diabetes. FDA February 2025 label change: REMOVED boxed warning for major adverse cardiovascular events; ADDED class-wide warning for blood pressure increases (per ambulatory BP monitoring data). Bhasin 1996 NEJM remains definitive demonstration of dose-dependent muscle gain in healthy men. Yeap 2026 J Clin Endocrinol Metab review: nonlinear association of low testosterone with all-cause mortality below ~213 ng/dL. **A 2026 randomized trial directly addresses the prostate-cancer contraindication.** Many guidelines treat a history of prostate cancer as a reason not to prescribe TRT, citing an absence of randomized evidence. This phase 2, double-blind, placebo-controlled trial (JAMA Internal Medicine, 2 academic centres, 136 men randomized, 125 completed) enrolled men 40+ with organ-confined low-grade prostate cancer — Gleason 6 or 3+4 — who had undetectable PSA for at least two years after radical prostatectomy and symptomatic hypogonadism. Over 12 weeks, testosterone cypionate 100 mg improved sexual activity (+0.91 daily events, 95% CI 0.56-1.26), sexual desire, quality-of-life sexual domain, negative affect, body composition, loaded stair-climbing power and peak VO2. **Erectile function did not change.** No participant in either arm had biochemical recurrence. The authors are explicit about the ceiling: the trial was "neither long enough nor large enough to evaluate clinical recurrence or long-term safety" and is a proof of concept to justify a larger study. It is 12 weeks in 136 highly selected post-prostatectomy men, not a general clearance — but it is the first randomized evidence where previously there was none.

Mechanism

Prototypical androgen receptor agonist; increases muscle protein synthesis, satellite cell activation, erythropoiesis, bone density; aromatizes to estradiol (necessary for bone, libido, lipids)

Studied, labeled, or reported dose & route

TRT: testosterone cypionate/enanthate 100-200 mg/week IM/subQ, or daily gel; supraphysiological cycles 300-1000+ mg/week

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Testosterone (TRT / supraphysiological)'s effects?
Read Off Label rates the evidence for Testosterone (TRT / supraphysiological) as Strong and the benefit magnitude as strong, producing an overall grade of B (6.8/10). TRAVERSE 2023 (n=5246, high CV risk hypogonadal men) — TRT non-inferior to placebo for MACE; no prostate cancer increase; small increases in atrial fibrillation, VTE, fractures, acute kidney injury.
What safety findings are reported for Testosterone (TRT / supraphysiological)?
Testosterone (TRT / supraphysiological) has a med risk profile in the database. Med (TRT); High (supraphysiological — erythrocytosis/HCT>54, HPG suppression/infertility, gynecomastia, acne, sleep apnea, prostate/BPH; CV risk NOT increased in TRT per TRAVERSE but unclear at supraphysiological doses) Legal status: Rx for hypogonadism (Schedule III US as anabolic steroid); illicit supraphysiological use illegal.
What doses or routes are reported for Testosterone (TRT / supraphysiological)?
TRT: testosterone cypionate/enanthate 100-200 mg/week IM/subQ, or daily gel; supraphysiological cycles 300-1000+ mg/week This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Testosterone (TRT / supraphysiological) work?
Prototypical androgen receptor agonist; increases muscle protein synthesis, satellite cell activation, erythropoiesis, bone density; aromatizes to estradiol (necessary for bone, libido, lipids)

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.